Complications of Implantable Cardioverter Defibrillator and Their Potential Risk Factors in Patients with Hypertrophic Cardiomyopathy

被引:0
|
作者
Goudarzi, Mohammad Taghi Hedayati [1 ]
Moradi, Maryam [2 ]
Abrotan, Saeed [1 ]
Saravi, Mehrdad [2 ]
Shirafkan, Hoda [3 ]
Irilouzadian, Rana [4 ]
Omran, Hossein Salehi [1 ]
机构
[1] Babol Univ Med Sci, Rohani Hosp, Sch Med, Dept Cardiol, Babol, Iran
[2] Babol Univ Med Sci, Fac Med, Dept Cardiol, Babol, Iran
[3] Babol Univ Med Sci, Hlth Res Inst, Social Determinants Hlth Res Ctr, Babol, Iran
[4] Iran Univ Med Sci, Burn Res Ctr, Tehran, Iran
关键词
SUDDEN-DEATH; TASK-FORCE; THERAPY; POPULATION; PREVENTION; EFFICACY; OUTCOMES; SOCIETY;
D O I
10.1155/2023/4552100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Hypertrophic cardiomyopathy (HCM) has different complications such as cardiac arrhythmia and sudden cardiac death (SCD). Insertion of an implantable cardioverter defibrillator (ICD) is recommended for HCM patients who are at high risk of SCD and malignant arrhythmias, despite having their own potential complications. Hypothesis. We aimed to investigate the prevalence of different complications of ICD insertion and the impact of the potential influential baseline characteristics in a one-year follow-up period. Methods. This was a retrospective study with a total of 71 HCM patients with ICD insertion. We evaluated the prevalence of different complications of ICD implantation and the impact of baseline characteristics on the occurrence of ICD complications using multivariate regression analysis in three 4-month periods. Results. In a one-year follow-up, 13 patients (18.3%) experienced at least one of the complications including pneumothorax, lead failure, ICD infection, inappropriate shocks, perforation, and upper limb deep vein thrombosis (DVT) with no mortality. Inappropriate shocks were reported as the most common (11.3%) complication during this period, with a gradual increase in the second (4.2%) and third (5.6%) follow-up sessions. Among all of the baseline characteristics that were investigated in this study, a positive history of hypertension was the only risk factor with significant impact on the occurrence of complications (P = 0.01). Conclusion. We demonstrated the occurrence of complications during a one-year follow-up as 18.3% in HCM patients with ICD insertion. A positive history of hypertension was the only baseline characteristic affecting the occurrence of complications, and inappropriate shocks were the most common complication.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] The Implantable cardioverter-defibrillator and hypertrophic cardiomyopathy.: Experience at three centers
    Marin, Francisco
    Gimeno, Juan R.
    Paya, Eduardo
    Garcia-Alberola, Arcadio
    Perez-Alvarez, Luisa
    Fernandez, Xusto
    de la Morena, Gonzalo
    Sogorb, Francisco
    Castro-Beiras, Alfonso
    Valdes, Mariano
    Martinez, Juan G.
    Monserrat, Lorenzo
    REVISTA ESPANOLA DE CARDIOLOGIA, 2006, 59 (06): : 537 - 544
  • [42] Efficacy of the implantable cardioverter-defibrillator for the prevention of sudden death in hypertrophic cardiomyopathy
    Maron, BJ
    Shen, WK
    Link, MS
    Epstein, AE
    Almquist, AK
    Daubert, JP
    Bardy, GH
    Rea, RF
    Favale, S
    Boriani, G
    Estes, NAM
    Spirito, P
    CIRCULATION, 1999, 100 (18) : 642 - 642
  • [43] Outcomes following implantable cardioverter-defibrillator therapy in children with hypertrophic cardiomyopathy
    Kaski, J. P.
    Esteban, M. T. Tome
    Lowe, M. D.
    Sporton, S.
    Rees, P.
    Deanfield, J. E.
    Mckenna, W. J.
    Elliott, P. M.
    EUROPEAN HEART JOURNAL, 2006, 27 : 397 - 397
  • [44] Outcomes following implantable cardioverter-defibrillator therapy in children with hypertrophic cardiomyopathy
    Kaski, J
    Esteban, MT
    Lowe, M
    Sporton, S
    Rees, P
    Deanfield, J
    McKenna, W
    Elliott, P
    HEART, 2006, 92 : A30 - A30
  • [45] Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy
    Kaski, Juan Pablo
    Esteban, Maria Teresa Tome
    Lowe, Martin
    Sporton, Simon
    Rees, Philip
    Deanfield, John E.
    McKenna, William J.
    Elliott, Perry M.
    HEART, 2007, 93 (03) : 372 - 374
  • [46] Audit of potential implantable cardioverter defibrillator patients
    Plummer, CJ
    McComb, JM
    EUROPEAN HEART JOURNAL, 2001, 22 : 20 - 20
  • [47] Sudden death as a presenting symptom of hypertrophic cardiomyopathy: Treatment with an implantable cardioverter defibrillator
    Talard, P
    Levy, S
    Bonal, J
    Paganelli, F
    Bouchiat, C
    Cellarier, G
    Dussarat, GV
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1996, 19 (08): : 1264 - 1267
  • [48] Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator
    Maron, BJ
    EUROPEAN HEART JOURNAL, 2000, 21 (24) : 1979 - 1983
  • [49] Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy
    McLeod, Christopher J.
    Ommen, Steve R.
    Ackerman, Michael J.
    Weivoda, Peggy L.
    Shen, Win K.
    Dearani, Joseph A.
    Schaff, Hartzell V.
    Tajik, A. Jamil
    Gersh, Bernard J.
    EUROPEAN HEART JOURNAL, 2007, 28 (21) : 2583 - 2588
  • [50] Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy
    Woo, Anna
    Monakier, Daniel
    Harris, Louise
    Hill, Ann
    Shah, Prasad
    Wigle, E. Douglas
    Rakowski, Harry
    Rozenblyum, Evelyn
    Cameron, Douglas A.
    HEART, 2007, 93 (09) : 1044 - 1045